JP2011513204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513204A5 JP2011513204A5 JP2010536259A JP2010536259A JP2011513204A5 JP 2011513204 A5 JP2011513204 A5 JP 2011513204A5 JP 2010536259 A JP2010536259 A JP 2010536259A JP 2010536259 A JP2010536259 A JP 2010536259A JP 2011513204 A5 JP2011513204 A5 JP 2011513204A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation according
- polymer
- active ingredient
- pharmaceutically active
- fine granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims description 77
- 239000008187 granular material Substances 0.000 claims description 76
- 238000002360 preparation method Methods 0.000 claims description 72
- 239000004480 active ingredient Substances 0.000 claims description 53
- 238000000576 coating method Methods 0.000 claims description 50
- 239000011248 coating agent Substances 0.000 claims description 49
- 229920001577 copolymer Polymers 0.000 claims description 48
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 38
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 36
- 239000011247 coating layer Substances 0.000 claims description 36
- 238000013270 controlled release Methods 0.000 claims description 36
- 239000007771 core particle Substances 0.000 claims description 26
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 24
- 239000010410 layer Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 239000010419 fine particle Substances 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 21
- -1 phthalate ester Chemical class 0.000 claims description 20
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 19
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 19
- 239000002245 particle Substances 0.000 claims description 17
- 239000004014 plasticizer Substances 0.000 claims description 16
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 13
- 239000001856 Ethyl cellulose Substances 0.000 claims description 12
- 238000005266 casting Methods 0.000 claims description 12
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 12
- 229920001249 ethyl cellulose Polymers 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 12
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 11
- 229920001800 Shellac Polymers 0.000 claims description 11
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 229960003943 hypromellose Drugs 0.000 claims description 11
- 239000004208 shellac Substances 0.000 claims description 11
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 11
- 229940113147 shellac Drugs 0.000 claims description 11
- 235000013874 shellac Nutrition 0.000 claims description 11
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical group CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 10
- 239000001069 triethyl citrate Substances 0.000 claims description 10
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 10
- 235000013769 triethyl citrate Nutrition 0.000 claims description 10
- 230000001419 dependent effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 3
- 239000000612 proton pump inhibitor Substances 0.000 claims description 3
- MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 claims description 2
- 229960003568 dexlansoprazole Drugs 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 2
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 2
- 229960003174 lansoprazole Drugs 0.000 claims description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 description 19
- 239000001913 cellulose Substances 0.000 description 19
- 235000010980 cellulose Nutrition 0.000 description 19
- 239000002702 enteric coating Substances 0.000 description 17
- 238000009505 enteric coating Methods 0.000 description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 16
- 239000008101 lactose Substances 0.000 description 16
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 8
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 6
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 4
- 239000012792 core layer Substances 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 239000004503 fine granule Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000001087 glyceryl triacetate Substances 0.000 description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229960002622 triacetin Drugs 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920003139 Eudragit® L 100 Polymers 0.000 description 2
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 2
- 229920003141 Eudragit® S 100 Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000593312 Selfia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- CYPSCVSJKNUDRN-UHFFFAOYSA-N C(C=C)(=O)OC.CC(C(=O)O)=C.C(C(=C)C)(=O)O Chemical compound C(C=C)(=O)OC.CC(C(=O)O)=C.C(C(=C)C)(=O)O CYPSCVSJKNUDRN-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003159 Eudragit® RS 100 Polymers 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002887 hydroxy group Chemical class [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 description 1
- JCPWEYMVKJCSHJ-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O.COC(=O)C(C)=C JCPWEYMVKJCSHJ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010536259A JP5604304B2 (ja) | 2008-03-11 | 2009-03-10 | 口腔内崩壊性固形製剤 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008061673 | 2008-03-11 | ||
| JP2008061673 | 2008-03-11 | ||
| JP2008334920 | 2008-12-26 | ||
| JP2008334920 | 2008-12-26 | ||
| PCT/JP2009/054983 WO2009113703A2 (en) | 2008-03-11 | 2009-03-10 | Orally-disintegrating solid preparation |
| JP2010536259A JP5604304B2 (ja) | 2008-03-11 | 2009-03-10 | 口腔内崩壊性固形製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011513204A JP2011513204A (ja) | 2011-04-28 |
| JP2011513204A5 true JP2011513204A5 (https=) | 2012-04-26 |
| JP5604304B2 JP5604304B2 (ja) | 2014-10-08 |
Family
ID=40791576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010536259A Expired - Fee Related JP5604304B2 (ja) | 2008-03-11 | 2009-03-10 | 口腔内崩壊性固形製剤 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9241910B2 (https=) |
| EP (1) | EP2254556A2 (https=) |
| JP (1) | JP5604304B2 (https=) |
| KR (1) | KR20100129761A (https=) |
| CN (2) | CN102026627B (https=) |
| AR (1) | AR070863A1 (https=) |
| AU (1) | AU2009224254A1 (https=) |
| BR (1) | BRPI0909439A2 (https=) |
| CA (1) | CA2717947C (https=) |
| CL (1) | CL2009000557A1 (https=) |
| CO (1) | CO6321224A2 (https=) |
| CR (1) | CR11709A (https=) |
| DO (1) | DOP2010000273A (https=) |
| EA (1) | EA021792B1 (https=) |
| EC (1) | ECSP10010538A (https=) |
| GE (1) | GEP20135845B (https=) |
| IL (1) | IL207989A0 (https=) |
| MA (1) | MA32174B1 (https=) |
| MX (1) | MX2010009824A (https=) |
| MY (1) | MY173730A (https=) |
| NZ (1) | NZ588407A (https=) |
| PE (2) | PE20141034A1 (https=) |
| TW (1) | TWI441658B (https=) |
| UY (1) | UY31698A (https=) |
| WO (1) | WO2009113703A2 (https=) |
| ZA (1) | ZA201006679B (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI441658B (zh) | 2008-03-11 | 2014-06-21 | Takeda Pharmaceutical | 口腔崩解固體製劑 |
| RU2011102777A (ru) * | 2008-06-26 | 2012-08-10 | МакНЕЙЛ-ППС, ИНК. (US) | Частицы с покрытием, содержащие фармацевтически активные агенты |
| EP3031451B1 (en) * | 2009-01-26 | 2018-03-07 | Shin-Etsu Chemical Co., Ltd | Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose |
| EP2319504A1 (en) * | 2009-11-07 | 2011-05-11 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical solid dosage form |
| WO2012001705A2 (en) * | 2010-06-29 | 2012-01-05 | Cadila Healthcare Limited | Pharmaceutical compositions of (r)-lansoprazole |
| BR112013014875A2 (pt) * | 2010-12-27 | 2016-10-18 | Takeda Pharmaceutical | tablete oralmente desintegrável |
| CN102716097A (zh) * | 2012-05-29 | 2012-10-10 | 浙江华海药业股份有限公司 | 控制口腔崩解片药物释放速率的方法 |
| FI126168B (en) | 2012-09-18 | 2016-07-29 | Novaldmedical Ltd Oy | A method for coating pharmaceutical substrates |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| JP6371866B2 (ja) * | 2015-02-10 | 2018-08-08 | 富士フイルム株式会社 | 口腔内崩壊錠及びその製造方法 |
| WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| EP3419659A1 (en) | 2016-02-23 | 2019-01-02 | The Regents of the University of Colorado, A Body Corporate | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens |
| EP3421032A4 (en) * | 2016-02-23 | 2019-10-23 | Nipro Corporation | PARTICULARS OF A PHARMACEUTICAL COMPOSITION, ORAL DECOMPOSITION PREPARATION THEREOF AND METHOD FOR PRODUCING PARTICLES OF A PHARMACEUTICAL COMPOSITION |
| GB201607548D0 (en) * | 2016-04-29 | 2016-06-15 | Univ Central Lancashire | Solid dosage form |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| JOP20190008A1 (ar) | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
| WO2018124284A1 (ja) * | 2016-12-28 | 2018-07-05 | 富山化学工業株式会社 | 医薬組成物 |
| PH12019500671B1 (en) * | 2017-02-21 | 2024-02-02 | Ea Pharma Co Ltd | Granular preparation |
| JP7235193B2 (ja) * | 2017-04-26 | 2023-03-08 | 大正製薬株式会社 | 固形組成物 |
| JP7009288B2 (ja) * | 2017-05-18 | 2022-01-25 | エルメッド株式会社 | 湿製錠剤の製造方法及び湿製錠剤の品質向上方法 |
| JP7336187B2 (ja) * | 2017-11-30 | 2023-08-31 | 日本ケミファ株式会社 | 多層構造を有する粒子状医薬組成物 |
| EP3740197A4 (en) | 2018-01-16 | 2021-11-10 | Applied Materials, Inc. | METAL OXIDE ENCAPSULATED COMPOSITIONS OF THE ACTIVE SUBSTANCE AND PROCESS FOR THEIR MANUFACTURING |
| KR20240160681A (ko) | 2018-01-24 | 2024-11-11 | 퍼듀 퍼머 엘피 | 수면 장애 치료 및 예방 |
| CN111836618A (zh) * | 2018-02-08 | 2020-10-27 | 景凱生物科技股份有限公司 | 类阿片受体拮抗剂的固体剂型用的医药剂型 |
| IL284564B2 (en) | 2019-01-31 | 2025-07-01 | Purdue Pharma Lp | Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound |
| EP4021423A4 (en) | 2019-08-27 | 2023-11-08 | Applied Materials, Inc. | Vapor phase coating technology for pharmaceutical abuse deterrent formulations |
| KR20220051385A (ko) | 2019-08-27 | 2022-04-26 | 어플라이드 머티어리얼스, 인코포레이티드 | 약제 용해도 조절을 위한 증기상 코팅들 |
| GB202001237D0 (en) * | 2020-01-29 | 2020-03-11 | Sisteks D O O | Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product |
| CA3168680A1 (en) | 2020-01-31 | 2021-08-05 | Nanocopoeia, Llc | Amorphous nilotinib microparticles and uses thereof |
| WO2021222739A1 (en) | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
| TWI870622B (zh) | 2020-10-02 | 2025-01-21 | 美商應用材料股份有限公司 | 製備氧化矽塗佈藥品的低溫處理 |
| CN112121067A (zh) * | 2020-11-16 | 2020-12-25 | 深圳科兴药业有限公司 | 一种婴儿型双歧杆菌微胶囊及其制备方法 |
| CN116887866A (zh) | 2020-12-03 | 2023-10-13 | 巴特尔纪念研究院 | 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法 |
| WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| CN117750958A (zh) | 2021-05-21 | 2024-03-22 | 普渡制药公司 | 治疗间质性膀胱炎/膀胱疼痛综合征的方法 |
| EP4408402A4 (en) | 2021-09-30 | 2025-08-06 | Applied Materials Inc | LOW TEMPERATURE SILICON OXIDE COATING FOR PHARMACEUTICAL APPLICATIONS |
| WO2023182332A1 (ja) * | 2022-03-22 | 2023-09-28 | 株式会社ダイセル | 口腔内崩壊錠用の添加剤組成物 |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| AU2024364388A1 (en) | 2023-10-19 | 2026-03-19 | Purdue Pharma L.P. | Sunobinop for use in method of treating alcohol use disorder |
| CN117180213A (zh) * | 2023-10-23 | 2023-12-08 | 湖南洞庭药业股份有限公司 | 奥沙西泮片组合物及其制备和稳定化方法 |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
| CN117860699A (zh) * | 2024-01-07 | 2024-04-12 | 长沙晶易医药科技股份有限公司 | 一种细粒剂及其制备方法 |
| KR20260019740A (ko) * | 2024-08-02 | 2026-02-10 | 일양약품주식회사 | 일라프라졸, 제산제 및 알칼리화제를 포함하는 안정한 약제학적 조성물 및 이의 제조방법 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62277322A (ja) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
| CA1327010C (en) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
| FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
| US5464632C1 (en) * | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
| SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| DK2263660T3 (en) | 1998-05-18 | 2018-01-02 | Takeda Pharmaceuticals Co | Orally disintegrating tablets. |
| ATE291418T1 (de) | 1998-07-28 | 2005-04-15 | Takeda Pharmaceutical | Leicht zerfallende feste zubereitung |
| WO2000018374A1 (en) | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| TWI289557B (en) * | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
| SK287902B6 (sk) * | 2001-01-31 | 2012-03-02 | Evonik Rohm Gmbh | Multiparticulate drug form and method for the preparation thereof |
| BR0211117A (pt) * | 2001-07-16 | 2004-06-22 | Astrazeneca Ab | Tablete multiparticulado, processo para a manufatura e uso do mesmo, e, método e tratamento de distúrbios gastrointestinais |
| DE10208335A1 (de) | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Arzneiform und Verfahren zu ihrer Herstellung |
| AUPS167602A0 (en) | 2002-04-12 | 2002-05-16 | F.H. Faulding & Co. Limited | An improved modified release preparation |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| US20040096497A1 (en) | 2002-11-19 | 2004-05-20 | Ponder Garratt W. | Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions |
| MXPA04010956A (es) * | 2003-01-30 | 2005-01-25 | Roehm Gmbh | Forma de dosis farmaceutica y metodo para la produccion de la misma. |
| US20060115529A1 (en) * | 2003-05-07 | 2006-06-01 | Seonghoon Jeong | Fast-melting tablets having taste-masking and sustained release properties |
| WO2005009410A2 (en) | 2003-07-17 | 2005-02-03 | Dr. Reddy's Laboratories, Inc. | Pharmaceutical compositions having a swellable coating |
| JP2007506775A (ja) | 2003-09-26 | 2007-03-22 | アルザ・コーポレーシヨン | 漸増する放出速度を表す制御放出製剤 |
| GB0323232D0 (en) * | 2003-10-03 | 2003-11-05 | Rolls Royce Plc | Electrical machine |
| EP1750717B1 (en) | 2004-02-11 | 2017-07-19 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| US20050181052A1 (en) | 2004-02-17 | 2005-08-18 | Patel Satishkumar A. | Lansoprazole microtablets |
| US20050214372A1 (en) | 2004-03-03 | 2005-09-29 | Simona Di Capua | Stable pharmaceutical composition comprising an acid labile drug |
| CA2557634A1 (en) | 2004-03-04 | 2005-09-15 | Takeda Pharmaceutical Company Limited | Stable capsule preparation |
| US8545881B2 (en) * | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
| CA2579767A1 (en) * | 2004-04-30 | 2005-11-10 | Astellas Pharma Inc. | Oral pharmaceutical composition in timed-release particle form and fast-disintegrating tablets containing this composition |
| DE102004035936A1 (de) | 2004-07-23 | 2006-03-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform |
| US20080063710A1 (en) | 2004-12-28 | 2008-03-13 | Eisai R&D Management Co., Ltd. | Rapidly Disintegrating Tablet and Production Method Thereof |
| GB0502479D0 (en) | 2005-02-07 | 2005-03-16 | Sb Pharmco Inc | Novel compositions |
| FR2885526B1 (fr) * | 2005-05-13 | 2007-07-27 | Flamel Technologies Sa | Medicament oral a base d'inhibiteur de pompe a protons |
| DE102005024614A1 (de) * | 2005-05-25 | 2006-11-30 | Röhm Gmbh | Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug |
| WO2006105798A2 (en) | 2005-07-11 | 2006-10-12 | Nycomed Danmark Aps | Benzimidazole formulation |
| DE102005032806A1 (de) * | 2005-07-12 | 2007-01-18 | Röhm Gmbh | Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten |
| WO2007037259A1 (ja) | 2005-09-29 | 2007-04-05 | Eisai R & D Management Co., Ltd. | 生体内での崩壊性を向上させたパルス製剤 |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
| JP2009519334A (ja) | 2005-12-20 | 2009-05-14 | テバ ファーマシューティカル インダストリーズ リミティド | ランソプラゾール経口崩壊錠剤 |
| EP1813275A1 (en) * | 2005-12-20 | 2007-08-01 | Teva Pharmaceutical Industries Ltd | Lansoprazole orally disintegrating tablets |
| EP1962844A2 (en) | 2005-12-20 | 2008-09-03 | Teva Pharmaceutical Industries Ltd | Lansoprazole orally disintegrating tablets |
| US8486450B2 (en) | 2005-12-28 | 2013-07-16 | Takeda Pharmaceutical Company Limited | Method of producing solid preparation disintegrating in the oral cavity |
| KR100762847B1 (ko) | 2006-01-27 | 2007-10-04 | 씨제이 주식회사 | 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법 |
| EP1837016A3 (en) | 2006-03-08 | 2008-01-02 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical multiple-unit composition |
| WO2007122478A2 (en) | 2006-04-20 | 2007-11-01 | Themis Laboratories Private Limited | Multiple unit compositions |
| NZ703464A (en) | 2006-04-26 | 2016-05-27 | Alphapharm Pty Ltd | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix |
| ES2466441T3 (es) | 2006-04-28 | 2014-06-10 | Wockhardt Limited | Composiciones farmacéuticas que comprenden fármaco antiinflamatorio no esteroideo, acetaminofén e inhibidor de la bomba de protones |
| KR20090038431A (ko) | 2006-06-19 | 2009-04-20 | 맥네일-피피씨, 인코포레이티드 | 활성 성분을 함유하는 장용 피복된 입자 |
| US20090291136A1 (en) | 2006-07-11 | 2009-11-26 | Lek Pharmaceuticals D.D. | Multiple Unit Tablets |
| US20090252787A1 (en) | 2006-07-28 | 2009-10-08 | Dr. Reddy's Laboratories Ltd. | Granular pharmaceutical compositions |
| KR101575679B1 (ko) | 2006-08-30 | 2015-12-08 | 자고텍 아게 | 코어 및 하나 이상의 배리어 층을 포함하는 방출 제어형 경구 투여 제제 |
| US9486446B2 (en) | 2006-12-28 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Orally disintegrating solid preparation |
| DE102007009242A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit magensaftresistenter Wirkstoff-Matix |
| DE102007009243A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| CA2687130C (en) | 2007-05-07 | 2017-10-03 | Evonik Roehm Gmbh | Solid dosage forms comprising an enteric coating with accelerated drug release |
| TWI441658B (zh) | 2008-03-11 | 2014-06-21 | Takeda Pharmaceutical | 口腔崩解固體製劑 |
| WO2010008569A1 (en) | 2008-07-17 | 2010-01-21 | Barr Laboratories, Inc. | Orally disintegrating solid pharmaceutical dosage forms comprising delayed-release lansoprazole and methods of making and using the same |
| BR112013014875A2 (pt) | 2010-12-27 | 2016-10-18 | Takeda Pharmaceutical | tablete oralmente desintegrável |
-
2009
- 2009-03-10 TW TW098107630A patent/TWI441658B/zh not_active IP Right Cessation
- 2009-03-10 BR BRPI0909439A patent/BRPI0909439A2/pt not_active Application Discontinuation
- 2009-03-10 EP EP09720410A patent/EP2254556A2/en not_active Withdrawn
- 2009-03-10 NZ NZ588407A patent/NZ588407A/en not_active IP Right Cessation
- 2009-03-10 EA EA201071054A patent/EA021792B1/ru not_active IP Right Cessation
- 2009-03-10 JP JP2010536259A patent/JP5604304B2/ja not_active Expired - Fee Related
- 2009-03-10 AR ARP090100842A patent/AR070863A1/es unknown
- 2009-03-10 WO PCT/JP2009/054983 patent/WO2009113703A2/en not_active Ceased
- 2009-03-10 GE GEAP2009011969 patent/GEP20135845B/en unknown
- 2009-03-10 AU AU2009224254A patent/AU2009224254A1/en not_active Abandoned
- 2009-03-10 CA CA2717947A patent/CA2717947C/en active Active
- 2009-03-10 KR KR1020107022551A patent/KR20100129761A/ko not_active Ceased
- 2009-03-10 CL CL2009000557A patent/CL2009000557A1/es unknown
- 2009-03-10 MY MYPI2010004253A patent/MY173730A/en unknown
- 2009-03-10 CN CN200980116971.XA patent/CN102026627B/zh not_active Expired - Fee Related
- 2009-03-10 US US12/921,731 patent/US9241910B2/en active Active
- 2009-03-10 UY UY0001031698A patent/UY31698A/es not_active Application Discontinuation
- 2009-03-10 PE PE2014000364A patent/PE20141034A1/es not_active Application Discontinuation
- 2009-03-10 PE PE2009000349A patent/PE20091620A1/es not_active Application Discontinuation
- 2009-03-10 CN CN201410370293.2A patent/CN104127368A/zh active Pending
- 2009-03-10 MX MX2010009824A patent/MX2010009824A/es not_active Application Discontinuation
-
2010
- 2010-09-05 IL IL207989A patent/IL207989A0/en unknown
- 2010-09-10 DO DO2010000273A patent/DOP2010000273A/es unknown
- 2010-09-17 ZA ZA2010/06679A patent/ZA201006679B/en unknown
- 2010-09-29 MA MA33210A patent/MA32174B1/fr unknown
- 2010-09-30 CR CR11709A patent/CR11709A/es unknown
- 2010-10-11 CO CO10125889A patent/CO6321224A2/es not_active Application Discontinuation
- 2010-10-11 EC EC2010010538A patent/ECSP10010538A/es unknown
-
2014
- 2014-10-21 US US14/519,979 patent/US20150037423A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513204A5 (https=) | ||
| US11147772B2 (en) | Timed, pulsatile release systems | |
| EP2276472B1 (en) | Compositions comprising weakly basic drugs and controlled-release dosage forms | |
| CN1886119B (zh) | 泮托拉唑多颗粒制剂 | |
| US9095513B2 (en) | Enteric coated granule and method for preparing the same | |
| CN101977593A (zh) | 包含弱碱性药物以及有机酸的给药系统 | |
| US20090004284A1 (en) | Controlled release tamsulosin hydrochloride formulation | |
| KR20160115995A (ko) | 지속 방출 특성을 가지며 에탄올의 영향에 대한 저항성을 갖는 약제학적 또는 건강기능성 조성물 | |
| JP2000053563A (ja) | 苦味がマスクされた速放性細粒剤 | |
| US20090136550A1 (en) | Modified release formulations of diltiazem | |
| JP2015151337A (ja) | 医薬用組成物の製造方法、医薬用組成物、及び口腔内崩壊錠 | |
| US20100080846A1 (en) | Dipyridamole and acetylsalicylic acid formulations and process for preparing same | |
| EP3184101A1 (en) | Levodopa and carbidopa modified release composition | |
| US20100239681A1 (en) | Controlled Release Particulates Containing Water-Insoluble Drug | |
| US20100303920A1 (en) | Aqueous Film Coating Composition / 841 | |
| AU2013273835B2 (en) | Timed, pulsatile release systems | |
| KR20110029250A (ko) | 양성자 펌프 억제제 함유 약학 조성물 | |
| HK1108116B (en) | Timed, pulsatile release systems | |
| HK1189799A (en) | Timed, pulsatile release systems |